JP2021520372A5 - - Google Patents
Info
- Publication number
- JP2021520372A5 JP2021520372A5 JP2020554235A JP2020554235A JP2021520372A5 JP 2021520372 A5 JP2021520372 A5 JP 2021520372A5 JP 2020554235 A JP2020554235 A JP 2020554235A JP 2020554235 A JP2020554235 A JP 2020554235A JP 2021520372 A5 JP2021520372 A5 JP 2021520372A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- leukemia
- compound according
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841015818 | 2018-04-26 | ||
| IN201841015818 | 2018-04-26 | ||
| PCT/IB2019/053443 WO2019207538A1 (en) | 2018-04-26 | 2019-04-26 | Pyridazine derivatives as smarca2/4 degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520372A JP2021520372A (ja) | 2021-08-19 |
| JP2021520372A5 true JP2021520372A5 (https=) | 2022-05-09 |
| JP7387630B2 JP7387630B2 (ja) | 2023-11-28 |
Family
ID=68295093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554235A Active JP7387630B2 (ja) | 2018-04-26 | 2019-04-26 | Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12371426B2 (https=) |
| EP (1) | EP3784665A4 (https=) |
| JP (1) | JP7387630B2 (https=) |
| CN (1) | CN112771038B (https=) |
| CA (1) | CA3118354A1 (https=) |
| SG (1) | SG11202104495YA (https=) |
| WO (1) | WO2019207538A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| PH12022550578A1 (en) * | 2019-09-12 | 2024-02-19 | Aurigene Discovery Tech Ltd | Method for identifying responders to smarca2/4 degraders |
| JP2023511471A (ja) * | 2019-10-28 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二官能性化合物 |
| JP2023511472A (ja) * | 2019-10-29 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二官能性化合物 |
| CN110790746B (zh) * | 2019-11-18 | 2020-10-30 | 南京恒通医药开发有限公司 | 一种利用微通道反应器连续化制备泊马度胺的合成工艺 |
| EP4081308A4 (en) * | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021142247A1 (en) | 2020-01-10 | 2021-07-15 | Amgen Inc. | Smarca2-vhl degraders |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4096651A4 (en) | 2020-01-29 | 2024-01-24 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12599671B2 (en) | 2020-02-12 | 2026-04-14 | Dana-Farber Cancer Institute, Inc. | Compounds, compositions, and methods for protein degradation |
| WO2021207291A1 (en) * | 2020-04-06 | 2021-10-14 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US11739101B2 (en) | 2020-05-06 | 2023-08-29 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US12570650B2 (en) * | 2020-08-04 | 2026-03-10 | Aurigene Oncology Limited | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| JP7723743B2 (ja) * | 2020-11-20 | 2025-08-14 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CN117337178A (zh) * | 2021-05-10 | 2024-01-02 | 福宏治疗公司 | 化合物及其用途 |
| KR20240004983A (ko) * | 2021-05-10 | 2024-01-11 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| CN115611881B (zh) * | 2021-07-13 | 2024-09-20 | 复旦大学 | 一种合成新型vhl配体4-f-vh032的方法 |
| KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
| US20250145609A1 (en) * | 2022-02-09 | 2025-05-08 | Aurigene Oncology Limited | 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2024064328A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024064316A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| CN121816356A (zh) * | 2023-07-28 | 2026-04-07 | 甘李药业股份有限公司 | 一种选择性降解smarca2/4的化合物及其应用 |
| CN118406019B (zh) * | 2024-07-02 | 2024-09-20 | 苏州源起材料科技有限公司 | 一种噻唑化合物生物医药砌块的合成方法 |
| WO2026061475A1 (zh) * | 2024-09-19 | 2026-03-26 | 标新生物医药科技(上海)有限公司 | 含有芳基取代杂芳基的双功能蛋白降解剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| PH12022550578A1 (en) * | 2019-09-12 | 2024-02-19 | Aurigene Discovery Tech Ltd | Method for identifying responders to smarca2/4 degraders |
-
2019
- 2019-04-26 EP EP19792591.0A patent/EP3784665A4/en active Pending
- 2019-04-26 CA CA3118354A patent/CA3118354A1/en active Pending
- 2019-04-26 JP JP2020554235A patent/JP7387630B2/ja active Active
- 2019-04-26 SG SG11202104495YA patent/SG11202104495YA/en unknown
- 2019-04-26 WO PCT/IB2019/053443 patent/WO2019207538A1/en not_active Ceased
- 2019-04-26 US US17/050,792 patent/US12371426B2/en active Active
- 2019-04-26 CN CN201980041999.5A patent/CN112771038B/zh active Active
-
2024
- 2024-03-19 US US18/609,175 patent/US20240270734A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520372A5 (https=) | ||
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| EP4422617A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2019535744A5 (https=) | ||
| JP2021519308A5 (https=) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| IL265115A (en) | Inhibitors of cellular metabolic processes | |
| JP2021512059A5 (https=) | ||
| CN109937041B (zh) | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2018138577A5 (https=) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2019535746A5 (https=) | ||
| JP2022071077A5 (https=) | ||
| JP2014525464A5 (https=) | ||
| JP2019516766A5 (https=) | ||
| JP2017530171A5 (https=) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2016501221A5 (https=) | ||
| JP2018510191A5 (https=) | ||
| JP2013518089A5 (https=) | ||
| JP2014513704A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2017524668A5 (https=) | ||
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2017507175A5 (https=) |